Coronary/Structural Heart

Celixir announces US FDA approval of the IND application for cell therapy Heartcel

Stratford-upon-Avon, UK, 08 June 2018 – Celixir, a privately owned company discovering and developing life-saving advanced therapies, announces that the US Food and Drug Administration (FDA) has approved its Investigational New Drug application (IND) for HeartcelTM, its immuno-modulatory progenitor (iMP) cell therapy for the treatment of adult heart failure. Celixir announced […]

Corindus Announces Pharmaceutical and Medical Device Agency (PMDA) Approval of CorPath GRX System in Japan

WALTHAM, Mass.–(BUSINESS WIRE)–Corindus Vascular Robotics, Inc. [NYSE American: CVRS], a leading developer of precision vascular robotics, announced today that it received Pharmaceutical and Medical Device Agency (PMDA) Approval for commercialization of its CorPath® GRX System in Japan. Japan is one of the largest markets in the world for percutaneous coronary interventions […]

Acasti Pharma to Present at the XVIII(th) International Symposium on Atherosclerosis

LAVAL, Québec, June 06, 2018 (GLOBE NEWSWIRE) — Acasti Pharma Inc. (NASDAQ:ACST) (TSX-V:ACST) (the “Company” or “Acasti Pharma”), a biopharmaceutical innovator focused on the research, development and commercialization of its prescription drug candidate CaPre® (omega-3 phospholipid) for the treatment of severe hypertriglyceridemia, today announced that the Company is scheduled to […]

Caladrius Biosciences Sells Rights to Counter-Flow Centrifugation System to Hitachi Chemical Advanced Therapeutics Solutions

BASKING RIDGE, N.J., June 05, 2018 (GLOBE NEWSWIRE) — Caladrius Biosciences, Inc. (Nasdaq:CLBS) (“Caladrius” or the “Company”), a clinical-stage biopharmaceutical company with multiple technology platforms targeting autoimmune and select cardiovascular indications, announces today that the Company has sold for $2.5 million its ownership interest in a development-stage, fully enclosed, automated, programmable […]

Emboline, Inc. Completes Initial Human Clinical Cases With The Emboliner™ Embolic Protection Catheter

SANTA CRUZ, Calif., June 5, 2018 /PRNewswire/ — Emboline, Inc., an emerging medical device company with a game-changing device for total embolic protection during transcatheter aortic valve replacement (TAVR) procedures, announced today the successful completion of its initial series of human clinical cases using the EmbolinerTM Embolic Protection Catheter. The initial procedures were performed at […]

Biomagnetic Imaging Company Genetesis Closes $7.5M in Series A Financing

MASON, Ohio–(BUSINESS WIRE)– Genetesis, a medical device company focused on using biomagnetic imaging to enable rapid, noninvasive and accurate chest pain triage, has closed an oversubscribed round of $7.5M in Series A financing. CincyTech led the round with participation from existing investors including Mark Cuban’s Radical Investments, and new investors including […]

TRiCares Closes €22 Million ($25.4 Million) Series B Financing Round to Fund Development of Minimally Invasive Treatment of Tricuspid Regurgitation

Paris, France and Munich, Germany, June 4, 2018 – TRiCares SAS, a privately held pioneer in the field of minimally invasive treatment of tricuspid regurgitation, is pleased to announce today the successful completion of a €22 Million ($25.4 Million) Series B financing round. Proceeds from the financing will be used to advance […]

Novoheart Becomes Member of International Consortium Advancing Cardiac Safety in Drug Development

VANCOUVER, British Columbia, May 31, 2018 (GLOBE NEWSWIRE) — Novoheart (“Novoheart” or the “Company”) (TSX-V:NVH) (FWB:3NH), a global stem cell biotechnology company, announced today that it has become a member of the Cardiac Safety Technical Committee of the Health and Environmental Sciences Institute (HESI), an industry-led, international consortium including major pharmaceutical and […]

EuroPCR Establishes Nobles Medical Technologies II As The Potential Leader In The Rapidly Growing PFO Closure Market

PARIS, May 31, 2018 /PRNewswire/ — Nobles Medical Technologies II, Inc. (NMT 2) today announced that following a highly successful showing at EuroPCR of the NobleStitch, the company will accelerate its sales, marketing and proctoring efforts to meet the increased demand in both existing countries and new territories.   The company noted receiving un-paralleled […]

Keystone Heart Ltd Announces First Enrollment in REFLECT Phase II incorporating TriGUARD 3™ Cerebral Embolic Protection device

CAESAREA, Israel and TAMPA, Fla., May 31, 2018 /PRNewswire/ — Keystone Heart Ltd., the leading medical device company focused on providing complete cerebral protection for patients undergoing cardiac procedures, today announced the launch of Phase II of the REFLECT trial to evaluate the safety and efficacy of the next generation of Keystone Heart […]